Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Non-Current Deffered Revenue (2016 - 2017)

Arcadia Biosciences' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $2.0 million for Q4 2017.

  • For Q4 2017, Non-Current Deffered Revenue fell 34.68% year-over-year to $2.0 million; the TTM value through Dec 2017 reached $2.0 million, down 34.68%, while the annual FY2017 figure was $2.0 million, 34.68% down from the prior year.
  • Non-Current Deffered Revenue reached $2.0 million in Q4 2017 per RKDA's latest filing, down from $2.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $3.6 million in Q4 2014 to a low of $2.0 million in Q4 2017.
  • Average Non-Current Deffered Revenue over 4 years is $2.8 million, with a median of $2.8 million recorded in 2017.
  • The largest YoY upside for Non-Current Deffered Revenue was 28.44% in 2017 against a maximum downside of 34.68% in 2017.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $3.6 million in 2014, then dropped by 27.48% to $2.6 million in 2015, then grew by 18.32% to $3.1 million in 2016, then crashed by 34.68% to $2.0 million in 2017.
  • Per Business Quant, the three most recent readings for RKDA's Non-Current Deffered Revenue are $2.0 million (Q4 2017), $2.8 million (Q3 2017), and $2.9 million (Q2 2017).